Adverse outcome pathways: opportunities, limitations and open questions

Author(s):
Leist, M.; Ghallab, A.; Graepel, R.; Marchan, R.; Hassan, R.; Bennekou, S.H.; Limonciel, A.; Vinken, M.; Schildknecht, S.; Waldmann, T.; Danen, E.; Ravenzwaay, B. van; Kamp, H.; Gardner, I.; Godoy, P.; Bois, F.Y.; Braeuning, A.; Reif, R.; Oesch, F.; Drasdo, D.; Hohme, S.; Schwarz, M.; Hartung, T.; Braunbeck, T.; Beltman, J.; Vrieling, H. (0000-0002-3034-2664); Sanz, F.; Forsby, A.; Gadaleta, D.; Fisher, C.; Kelm, J.; Fluri, D.; Ecker, G.; Zdrazil, B.; Terron, A.; Jennings, P.; Burg, B. van der; Dooley, S.; Meijer, A.H.; Willighagen, E.; Martens, M.; Evelo, C.; Mombelli, E.; Taboureau, O.; Mantovani, A.; Hardy, B.; Koch, B.; Escher, S.; Thriel, C. van; Cadenas, C.; Kroese, D.; Water, B. van de; Hengstler, J.G.
Published
2017
Publication type
Article / Letter to editor
Regulatory toxicologySystems biologyMulti-scale integrationComputational toxicologyInterspecies extrapolationMetabolismPathway unidirectionalityLiver fibrosisParacetamolCCl4Vinyl acetateTumor promotionBinning of eventsMultiple hit events Proof of non-toxicityPrioritization of compounds
Date issued
2017-11-30
Language
English
Is part of
Archives of Toxicology (2017), Vol. 91, no. 11, p. 3477-3505
hdl
1887/116015
doi
10.1007/s00204-017-2045-3